FDA Drafts Clever Trials for Rare Gene Therapy Cures
Published Date: 9/25/2025
Notice
Summary
The FDA just dropped a draft guide to help companies testing cell and gene therapies for rare diseases. It shows smart ways to design clinical trials that speed up getting these treatments approved without cutting corners. If you’re developing these therapies, this could save time and money while making sure the treatments really work.
Analyzed Economic Effects
3 provisions identified: 3 benefits, 0 costs, 0 mixed.
Designs and endpoints to support licensure
The draft guidance describes FDA requirements and provides considerations for using various clinical trial designs and endpoints to generate clinical evidence that supports product licensure. It is aimed at helping sponsors plan how to collect the evidence the FDA will consider for approval.
Promotes innovative designs to expedite development
The guidance recommends that sponsors developing CGTs for small populations leverage innovative trial designs to simultaneously expedite drug development and generate the data necessary to demonstrate substantial evidence of effectiveness. The recommendation is targeted to sponsors of CGT products intended for small populations.
Draft guidance for CGT in rare diseases
If you sponsor cell or gene therapy (CGT) trials for diseases that meet the rare disease definition under section 526(a)(2) (21 U.S.C. 360bb(a)(2)), the FDA released a draft guidance titled "Innovative Designs for Clinical Trials of Cellular and Gene Therapy Products in Small Populations." The document is intended for sponsors planning trials of CGT products in small populations.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-13047 — Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-13778 — Medical Device User Fee Amendments; Public Meeting; Request for Comments
The FDA is planning a public meeting on August 5, 2026, to talk about renewing fees that medical device makers pay to help speed up device reviews from 2028 to 2032. This affects companies making medical devices and could impact how much they pay and how fast their products get approved. The current fee program ends in September 2027, so the FDA wants your thoughts before finalizing new rules and fees.
2026-13716 — New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of Sponsor
The FDA just updated the rules for new animal drugs, approving several new and generic medicines for pets and farm animals from early 2026. These changes help keep animal treatments safe and effective, and the updates take effect right away on July 7, 2026. If you’re a drug maker or animal caretaker, these approvals and sponsor changes could impact what medicines are available and when.
2026-13616 — Endo Operations Limited, et al.; Withdrawal of Approval of 34 New Drug Applications
The FDA is officially pulling the plug on 34 drug approvals because the companies stopped selling these medicines. This change kicks in on August 5, 2026, and it mainly affects drug makers like Endo Operations and Pfizer. No money penalties here—just a clean break, but companies can ask to reapply if they want to bring the drugs back.
2026-13534 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Administrative Practices and Procedures; Formal Hearings
The FDA is asking for public feedback on how it collects information for formal hearings and administrative rules. This affects businesses and people who interact with the FDA, with no new costs but a chance to improve paperwork processes. Comments are due by August 5, 2026, so don’t miss your chance to weigh in!
2026-13519 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Premarket Approval of Medical Devices
The FDA is asking for public feedback on their paperwork rules for approving the most important and risky medical devices, like life-support machines. This review helps keep devices safe and effective before they hit the market. If you have thoughts, you’ve got until August 5, 2026, to share them—no cost changes, just a check-in on the info they collect.
Previous / Next Documents
Previous: 2025-18650 — Postapproval Methods To Capture Safety and Efficacy Data for Cell and Gene Therapy Products; Draft Guidance for Industry; Availability
The FDA just dropped a draft guide to help companies track how safe and effective cell and gene therapies are after they hit the market. This is big for drug makers because these therapies can have long-lasting effects, and we need to keep an eye on them beyond initial tests. Companies should get ready to collect and share ongoing data, which might mean extra work and costs down the road.
Next: 2025-18653 — Expedited Programs for Regenerative Medicine Therapies for Serious Conditions; Draft Guidance for Industry; Availability
The FDA just released a draft guide to speed up the development and review of new regenerative medicine treatments for serious illnesses. This update helps companies bring life-changing therapies to patients faster and could save time and money. If you’re working on these cutting-edge treatments, keep an eye out for the final version soon!